Biogen's Reata Pharmaceuticals acquisition brings Skyclarys, the first and only FDA-approved therapy for the rare neuromuscular disease Friedreich’s ataxia. Biogen says Skyclarys complements the other neuromuscular drugs in its portfolio.
Skyclarys, a Reata Pharmaceuticals drug, is now approved for treating the rare neuromuscular disorder Friedreich’s ataxia. The decision makes the capsule the first therapy for a disease that’s rarer than either Duchenne muscular dystrophy or spinal muscular atrophy.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The FDA placed a clinical hold on a Larimar Therapeutics program for Friedreich's ataxia after monkeys died in tests of the fusion protein. In addition to halting further tests of the drug, the clinical hold also ends the biotech's plan to raise $95 million that would have funded clinical research.
Shares of Texas-based Reata rose 60 percent Tuesday following the announcement of results from its registration-directed Phase II study of omaveloxolone. The company reacquired rights to that and other drugs from AbbVie last week. FA has no approved treatments.
There’s a generalized consensus that “good” fats – like Omega-3 fatty acids – could help improve mental acuity, even combat neurodegenerative disease. Bay Area startup Retrotope is riffing off this idea, engineering what could be a super-good fat that treats aging-related conditions like Alzheimer’s, Parkinson’s and diabetic retinopathy. It just received $6.5 million in angel funding to bring its fatty drug to the […]